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Abstract. Commonly used Alzheimer’s disease mouse models are based on the ectopic overexpression of the human amyloid
precursor protein (APP) gene, together with a mutant presenilin gene. Surprisingly, humanized APP knock-in mouse models
carrying a single APP Swedish mutation (AppNL), failed to develop amyloid plaque aggregation or cognitive deficits. Here
we characterized the effect of this mutation in more advanced ages. We show that 24-month-old AppNL/NL mice, despite
presenting an age dependent increase in insoluble amyloid- oligomers in the prefrontal cortex, they do not develop amyloid
plaque deposition, reactive gliosis, or cognitive deficits.
Keywords: Aging, Alzheimer’s disease, amyloid plaques, behavior, cognition, knock-in
INTRODUCTION
Alzheimer’s disease (AD) is a devastating neurode-
generative disorder characterized by the presence of
intracellular neurofibrillary tangles and extracellular
amyloid plaques [1]. The latter are mainly composed
by aggregation of amyloid- (A) peptides, produced
by a proteolytic cleavage of the amyloid- protein
precursor (APP) by - and -secretases [2]. While
the etiology of the vast majority of AD cases remains
still unknown, there are rare forms of the disease
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(<1%) that are caused by inherited mutations in APP
or presenilins (PS), the catalytic subunit of the -
secretase. These mutations affect APP processing
by -secretase, favoring the release of longer and less
soluble A peptides [3, 4].
The discovery of familial AD (FAD) mutations
allowed the development of different mouse models
that could recapitulate most of the symptoms of AD
including the presence of amyloid plaques, increased
tau phosphorylation, reactive gliosis and cognitive
impairments [5]. Nevertheless, most of these models
overexpress APP and PS transgenes, which has been
associated with side effects and artificial phenotypes
[6].
To overcome this problem, Saito et al. devel-
oped three new APP knock-in mouse models
for AD, which express a humanized A sequence
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carrying either one (Swedish AppNL), two (Swedish
and Iberian AppNL−F ), or three (Swedish, Iberian,
and Artic AppNL−G−F ) FAD mutations [7]. Interest-
ingly, only the models with the double (AppNL−F )
or the triple (AppNL−G−F ) APP mutations show
signs of AD including amyloid plaques deposits,
while mice carrying the single Swedish mutation
(AppNL/NL) failed to develop plaques, reactive glio-
sis, or cognitive deficits [7, 8]. The Swedish mutation
is located in the -cleavage site and it triggers a 2.5
increase in APP and A production [7]. In patients,
heterozygous Swedish mutation leads to early-onset
AD with a mean age of onset of 55 years [9]. The
AppNL/NL model has only been characterized at 18
month of age [7, 8], a time when the animals have not
undergone the full gamut of aging-related alterations
[10]. Therefore, it would be important to determine
whether the absence of behavioral defects in these
mice is due to an insufficient aging phenotype.
For these reasons, in this study we characterized
the effect of the single Swedish mutation in homozy-
gous 24-month-old AppNL/NL male mice, compared
to age- and sex-matched C57Bl/6J mice.
MATERIALS AND METHODS
Aβ extraction and ELISA detection
For soluble A extraction, frozen pre-frontal
cortices were homogenized in tissue protein extrac-
tion reagent (Pierce). Samples were spun down
5 min at 5,000× g and supernatants centrifuged
1 h at 100,000× g. Supernatants were recovered
as the soluble fraction. To extract the deposited
A, pellets were solubilized with GuHCl (6 M
GuHCl/50 mM Tris-HCl), sonicated and centrifuged
20 min at 70,000 rpm. For A quantification, ELISA
Meso Scale Discovery (MSD) 96-well plates coated
with the human antibody for A40 or A42 (Janssen
Pharmaceutica) were used.
Immunohistochemistry
Mice were intracardially perfused with 4%
paraformaldehyde (PFA) solution and brains were
cut into 50m-thick slices using a Leica VT1000S
vibratome. Before immunohistochemistry, antigen
retrieval was performed in boiling 10 mM tri-Sodium
Citrate buffer pH 6.0. After blocking, slices were
incubated with antibodies against Iba 1 (Wako #
019-19741) and 6E10 (BioLegend #803003) and
the corresponding Alexa secondary antibodies. After
the washes, slices were incubated with Thioflavin-
S and dehydrated using increasing concentrations of
ethanol.
Behavioral tests
AppNL/NL and C57/Bl6 male mice were housed in
standard mouse cages (3–5 mice per cage) with wood-
shaving bedding. Food and water were available
ad libitum in temperature- and humidity-controlled
rooms with a 12-h light-dark cycle. All experiments
were approved by the institutional ethical committee
of the KU Leuven for use on experimental animals.
Open ﬁeld
Locomotor activity was measured in a
50 cm × 50 cm arena with bright illumination.
Before the test, mice were habituated to the dark for
30 min. Movement was recorded and analyzed using
ANY-maze™ Video Tracking System software
(Stoelting Co., IL, USA).
Elevated plus maze
The elevated plus maze had two open arms and
two enclosed arms opposite to each other and ele-
vated 30 cm from the surface. Mice were located at
the center of the maze and for 10 min the activity was
monitored using five infrared beams.
Contextual and cued fear conditioning
Mice were first habituated for 5 min in the StartFear
cage with a specific context. 24 h later animals were
placed in the same cage and exposed two times to
a 30 s tone (4 kHz, 80 dB) which co-terminated with
an electric shock (2 s, 0.3 mA). The next day, mice
were placed again in the same context and freezing
was quantified for contextual fear memory. To assess
cued memory, the context of the cage was changed (in
the visual, tactile, and olfactory dimension) and after
3 min of habituation, animals were exposed to the
tone (cue). The percentage of freezing was calculated
as reliable readout for fear in rodents.
Social preference/social novelty
The test consisted in three chambers. The left and
right chamber contained cylindrical wire cups, and
were connected to the central chamber via guillo-
tine doors. In the first trial, mice were habituated for
5 min to the central chamber. Immediately after, a
stranger mouse (stranger 1) was placed in one of the
wire cups, doors were opened and the test mice was
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left for free exploration during 10 min (Social pref-
erence). Finally, in the last trial (social novelty), a
novel mouse (stranger 2) was placed in the second
wire cup and test mouse was allowed to explore either
stranger 1 or stranger 2 for 10 min. Mice movement
was recorded and analyzed with ANY-maze™ Video
Tracking System software (Stoelting Co., IL, USA).
Morris water maze
A circular pool was filled with white-painted water
and a scape platform was placed 0.5 cm below the
water surface. Mice were trained for 10 days (4 tri-
als/day) to find the hidden platform starting randomly
from 4 different positions. Probe trials were per-
formed on day 6 and day 11 by removing the platform
and the search pattern of mice was recorded for 100
seconds using EthoVision® video tracking (Noldus,
Wageningen, the Netherlands).
RESULTS
APP knock-in mice carrying the double
(AppNL−F ) and the triple (AppNL−G−F ) mutations
showed an age-dependent increase of soluble and
guanidine hydrochloride (GuHCl)-extracted A42
levels [7]. To analyze whether AppNL/NL aged mice
also show accumulation of A peptides, we homog-
enized prefrontal cortex from AppNL/NL mice at 6,
18, and 24 months of age (n = 4, 6, and 8, respec-
tively) and we measured A levels using mesoscale
MSD ELISA plate coated with human-specific anti-
bodies against A40 and A42 peptides. Intriguingly,
AppNL/NL mice showed decreased levels of soluble
A40 (p = 0.042, 1-way ANOVA Tukey’s post-hoc
test, Fig. 1A) and A42 (p = 0.044, 1-way ANOVA
Tukey’s post-hoc test, Fig. 1B) between 18 and 24
months of age. However, when we extracted the
deposited fractions using GuHCl, we found a signifi-
cant increase of A40 (6 versus 18 MO: p = 0.0175; 6
versus 24 MO: p = 0.0007, 1-way ANOVA Tukey’s
post-hoc test, Fig. 1C) and A42 (6 versus 18
MO: p = 0.008; 6 versus 24 MO: p = 0.0215, 1-way
ANOVA Tukey’s post-hoc test, Fig. 1D) in the aged
groups (18 and 24 months of age) compared to the
young group of 6 months of age.
To further elucidate whether the increased levels of
non-soluble A peptides resulted in amyloid plaque
deposits in the brain, we stained AppNL/NL coro-
nal brain sections with Thioflavin and with the 6E10
antibody against human A. As a positive control, we
included sections from 8-month-old APP/PS1 mice,
overexpressing APP and the PS1 genes with FAD
mutations [11], where we observed clear A deposits
in the cortex and hippocampus (Fig. 1E). Nonethe-
less, when we analyzed sections from 24-month-old
AppNL/NL mice and age-matched wild-type (WT)
controls, no amyloid deposits could be detected in
the cortex, hippocampus (Fig. 1E), or prefrontal cor-
tex (Supplementary Figure 1) (n = 4). In addition,
we also studied potential signs of gliosis by staining
the slices with the microglia-specific marker, Iba1.
Accordingly, we found no changes in number and
reactivity of microglial cells in old AppNL/NL mice
compared to WT (n = 4) (Fig. 1E).
The absence of amyloid plaques in mice with high
levels of insoluble forms of A led us to speculate that
cognitive defects might have occurred, since there
are numerous studies suggesting that an excess of
oligomers affects synaptic function [12–14]. Thus,
we studied the cognitive functions of 24-month-old
AppNL/NL mice compared to WT from the same
B57Bl/6J background (n = 11–12 animals per group).
Experiments were carried out blinded, and random-
ized between different genetic groups.
We started assessing locomotor activity using the
open field task. During this test, mice were placed in
a bright arena for 10 min of free exploration while
their trajectories were tracked. Previous models for
AD displayed an increased locomotor activity [15].
However, here we show no significant differences in
average speed and total distance travelled between
AppNL/NL and WT mice (Fig. 2A, B).
AD has also been associated with changes in anx-
iety [15, 16]. Time spent or entries to the brightly lit
center can reflect anxiety-related behavior: the more
anxious the mouse is, the less often it will venture
into the open unprotected center. However, we mea-
sured no difference in center exploration between the
genotypes, with all mice spending most of their time
close to the walls (Fig. 2C). In the elevated plus maze
(Fig. 2D), AppNL/NL mice were significantly more
active than WT (total arm visits WT: 105 ± 4.97;
AppNL/NL: 131 ± 7.33 p = 0.0091, unpaired t-test,
Fig. 2E), but were not visiting the open arms more fre-
quently (WT: 16.68 ± 1.7; AppNL/NL: 20.14 ± 2.28,
p = 0.24, unpaired t-test, Fig. 2F). The increased total
number of entries might reflect a general hyperac-
tivity specifically toward closed (dark) arms, since
this hyperactivity is not observed in other activity-
sensitive readouts, such as speed or distance travelled
in the open field. This could indicate that when these
two groups of animals are exposed to the brightly
lit open field after a period of dark adaptation, all
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Fig. 1. Increased insoluble amyloid- oligomers in aged AppNL/NL mice. A, B) ELISA detection of soluble A40 (A) and A42 (B)
peptides in the prefrontal cortex from 6 (n = 4), 18 (n = 6), and 24 (n = 8) month-old AppNL/NL mice. C, D) ELISA detection of aggregated
GuHCl-extracted fractions of A40 (C) and A42 (D) peptides in the prefrontal cortex from 6 (n = 5), 18 (n = 6), and 24 (n = 8) month-old
AppNL/NL mice. Statistical significance (∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001) was evaluated using 1-way ANOVA Turkey’s post-hoc test.
E) Representative images from hippocampal and cortical areas from 8-month-old APPswePS1 mice, or 24-month-old WT or AppNL/NL
mice stained with Thioflavin (green) and 6E10 (blue) or Iba1 (red)antibody. n = 4 mice per group. Scale bar represents 100m.
animals would choose the same avoidance behavior
and stay close to the wall. However, when presented
a choice of open or closed arms, AppNL/NL would
be more active in the relative safety of the closed
arms.
In the clinic, altered social interaction and social
recognition have been associated with AD [17], alter-
ation which has been recapitulated in animal models
for the disease [18]. Here, we assessed social behav-
ior and recognition memory by presenting either a
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Fig. 2. No major locomotor and anxiety-related alterations in 24-month-old AppNL/NL mice. A) Average mean speed and distance travelled
(B) during the 10 min free exploration in the open field. C) Time spent in the center versus the periphery areas in the open field task n = 12
WT; 11 AppNL/NL mice. D) Explanatory diagram showing the 2 open and 2 closed arms from the elevated plus maze. E) Elevated plus
maze shows an increased number of total entries to the open and closed arms in old AppNL/NL (n = 8) mice compared to WT (n = 9). F)
No differences in the percentage of entries to the open arms, normalized to the total number of entries between the two genetic groups.
Histograms show the mean (±S.E.M). Statistical significance (∗p < 0.05, ∗∗p < 0.005) was evaluated with an unpaired T-test.
stranger mouse and an object (social approach) or a
familiar and novel stranger mouse (recognition mem-
ory). In the social approach phase, preference for
exploring a mouse over an object (empty cage) was
recorded for 10 min and discrimination index was
calculated by [(Time stranger 1-Time object)/ (Time
stranger 1 + Time object)]. Our analysis indicated that
both genotypes preferred the stranger mouse over the
empty cage, and there were no differences between
the genotypes (Fig. 3A). When we tested social
recognition memory, we observed that AppNL/NL
mice spent more time with the novel stranger, while
WT did not show this preference (one sample t
test comparing discrimination index to chance (=0):
AppNL/NL, p = 0.002; WT, p = 0.57; Fig. 3B). This
may indicate an impairment in social discrimina-
tion in old B57Bl/6J animals, which was not present
in the AppNL/NL mice. Discrimination index was
calculated as [(Time stranger novel- Time stranger
familiar)/ (Time stranger novel + Time stranger famil-
iar)].
Then, spatial learning and memory was evaluated
in the Morris water maze. Mice were trained for 10
consecutive days (4 trials/day; 15–30 min inter-trial
interval) to find a hidden platform (15 cm) in a circular
pool (150 cm). To assess spatial reference memory,
we performed 2 probe trials after 5 (probe trial 1)
and 10 (probe trial 2) days. During these trials the
platform was removed and the swimming trajectories
were tracked to quantify the amount of time mice
swam in the target quadrant where the platform was
located.
AppNL/NL mice displayed delayed learning dur-
ing the first 5 days of the training (F(1,19) = 10.19;
p = 0.005, RM-ANOVA, group factor, Fig. 3C). But
the performance equalized in the second week of
training, indicating that AppNL/NL mice did learn
to find the hidden platform but needed more time
to reach the same performance as the WT controls
(Fig. 3C, Supplementary Figure 2A, B).
Probe trials revealed accuracy to remember a cer-
tain spatial location. Both groups needed 2 weeks of
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Fig. 3. 24-month-old AppNL/NL mice show no defects in spatial and social learning and memory. A) Social preference test revealed
no alterations in the mean discrimination ratio: (Time STR1-Time empty)/ (Time STR1+Time empty). B) Social novelty test showed no
differences in the mean discrimination index between 24-month-old WT (n = 8) and AppNL/NL (n = 11) mice: (Time STR1-Time STR2)/
(Time STR1+Time STR2). C) Acquisition curve in the Morris water maze test compares the latency to find the hidden platform during the
10 training days between WT and 24-month-old AppNL/NL mice. D) Probe trial 1 (performed after 5 days of training) and (E) probe trial
2 (performed after 10 days of training) revealed no differences in the time spent swimming in the target quadrant between the two groups.
F, G) Contextual and cued-fear conditioning test: Graphs shows mean percentage of freezing during the context test (F); or the cued test
(G). n = 10 WT, 11 AppNL/NL mice. Histograms show the mean (±S.E.M). Statistical significance was analyzed with unpaired T-test (A,
B, D-G) and with repeated measurements 2-way ANOVA (C).
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training to demonstrate a robust preference for the tar-
get quadrant. This preference was not above chance
(=25%) in probe trial 1, but in probe 2, the time spent
in the target quadrant was significantly above 25% in
both groups, without genotype differences (Fig. 3D,
E, Supplementary Figure 2C, D). This allows for the
conclusion that AppNL/NL learned slower than WT,
but both groups needed 2 weeks of training to show
robust spatial reference memory.
Finally, we assessed the contextual fear memory in
old AppNL/NL mice using contextual and cued fear
conditioning test. In this test, mice received an elec-
tric shock paired with a tone in a specific context. 24 h
later, animals were placed in the same context and the
amount of freezing was quantified as a read-out for
fear memory. Figure 3E revealed comparable freez-
ing between old AppNL/NL and WT animals during
the context test. To analyze whether the mice were
able to associate the aversive electric shock with the
conditioned stimulus, animals were placed in a new
context and exposed to the same acoustic stimulus
that was previously paired with shock. Similarly, to
the context test, percentage of freezing in the cued test
was not affected in AppNL/NL mice compared to WT
controls (Fig. 3F). In conclusion, we did not observe
any genotype effect in contextual fear conditioning.
However, we observed a rather high variability in
freezing between the animals. Therefore, we ana-
lyzed whether freezing (readout for fear memory)
correlated with the amount of A in the brain. As
shown in Supplementary Table 1, we did not find a
significant correlation with any of the different A
peptides.
In conclusion, we find very subtle, but genotype-
specific differences in Morris water maze learning but
not in reference memory, in social recognition but not
social approach, and in activity in safe spaces but not
in open field.
DISCUSSION
To conclude, in this work we provide for the first
time a complete behavioral and biochemical charac-
terization of the aged AppNL/NL mice, which in our
view, is the closest model mimicking molecularly
one genetic human AD condition (Swedish muta-
tion). The results presented here revealed that the
Swedish mutation alone, despite inducing an age-
dependent increase of insoluble A levels, was not
sufficient to trigger amyloid plaques deposition, reac-
tive gliosis, or major cognitive deficits, even when
combined with aging in 24-month-old AppNL/NL
mice.
Intriguingly, the increased levels of insoluble A
with age were accompanied by decreased levels of
A in the soluble fraction. This is similar to what
happens in AD brains, where it has been shown
that the percentages of soluble A40 and A42 were
also decreased compared to healthy brains, as the
insoluble percentages increased [19]. One possi-
ble explanation for this phenotype would lie in the
general impairment of the “protein quality control”
machinery that associates with age [20, 21].
We also found it surprising that in this model, the
increased levels of insoluble A oligomers in old
AppNL/NL mice did not result in amyloid plaques
deposition in the brain. This might suggest that A
oligomers only start aggregating above certain thresh-
old that was not reached in the brains from old
AppNL/NL mice. Alternatively, it could also suggest
the activation of protective proteolytic or survival
pathways in this model, which prevent the develop-
ment of an AD phenotype [22].
Interestingly, the APP23 mouse model overex-
pressing human APP Swedish under the Thy1.2
promoter shows amyloid plaques and massive glia
reaction in hippocampus and cortex at 6 months
of age [23]. In addition, APPswe mice expressing
human APP Swedish under the neuron-specific eno-
lase promoter (NSE), exhibit cognitive alterations in
the Morris water maze test at the age of 12 months
[24]. These studies, compared to the data shown here,
suggest that the ectopic expression of the APP trans-
gene, might be partially responsible for the observed
AD-related alterations, instead of the Swedish muta-
tion itself. In fact, overexpression of human WT
APP gene alone has been reported to cause memory
impairments [25]. Supporting the notion that AD-like
phenotype can be due to ectopic expression, the gen-
eral behavioral phenotype from the APP knock-in
models generated by Saito, is surprisingly mild com-
pared to other overexpression models. For example,
the AppNL−G−F model carrying three APP muta-
tions, shows an accumulation of amyloid plaques
already at 6 months of age [7], but does not exhibit
defects in spatial learning, assessed with the place
preference task. Regarding behavioral alterations,
while Masuda et al. described an impaired spatial
reversal learning in 13–14-month-old AppNL−G−F
mice [8]; Latif-Herna´ndez et al., reported no defects
in spatial reversal reference memory in the Morris
water maze test at 12 months of age [26]. In this work,
we observed a mild delay in spatial learning during
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the first 5 days of acquisition in the Morris water maze
test in 24-month-old AppNL/NL mice. However, this
delayed learning did not affect the memory for the
platform location during the probe trials.
Overall, the altered cognitive abilities described in
any of the mentioned studies, including ours, were
minimal compared to the phenotypes described in
the more aggressive overexpression models such as
APP/PS1 [11] or 5xFAD [27].
Another possible explanation for the absence of
major behavioral phenotype in these animals is the
lack of tau pathology, which is needed in combination
with amyloidosis to trigger cognitive deficits [28, 29].
In this work, we have not characterized the levels
of tau phosphorylation in the aged AppNL/NL mice.
However, in the original paper, Saito et al. reported
no changes in tau phosphorylation in the knock-in
models [7].
One possible confounder in the current study is that
Ameasurements were done in the same animals that
previously underwent the battery of behavioral tests.
Thus, an effect of the behavioral activities on amyloid
production cannot be excluded, i.e., physical exercise
and environmental enrichment has been suggested to
reduce A levels and amyloid deposition [30, 31].
In addition, it is important to note that the old ages
of the animals may impair their acoustic and visual
capacities which can interfere with the behavioral test
[32, 33]. However, all animals were able to find the
platform, and show a significant increase of freezing
in the cued test, suggesting their capability to detect
the external visual and auditory cues was not affected.
Altogether, in this paper we have shown that in
mouse models, a single APP mutation expressed
under physiological levels is not sufficient to trigger
amyloid plaques or major cognitive deficits despite
increased levels of insoluble A oligomers. Further
work is needed to determine the murine-specific fac-
tors preventing amyloid plaque accumulation in this
model or human specific factors enhancing these
effects.
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